Stock of the Day
July 9, 2019
Krystal Biotech (KRYS)
$134.87
+$2.25 (+1.7%)
Market Cap:
$3.90B
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
← Previous Stock of the Day
Next Stock of the Day →
Recent News
Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference
(finance.yahoo.com)
Implied Volatility Surging for Krystal Biotech Stock Options
(msn.com)
Krystal Biotech Enters Oversold Territory (KRYS)
(nasdaq.com)